Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

Cited In for PubMed (Select 17568025)

1.

Medicare coverage for erythropoiesis-stimulating agents: the perfect storm.

Interview (Part 1) with Samuel M. Silver, MD, PhD.

Am Health Drug Benefits. 2008 May;1(4):46-50.

2.

Supportive care in hemato-oncology: a review in light of the latest guidelines.

Gündüz E, Gülbaş Z.

Turk J Haematol. 2012 Mar;29(1):1-9. doi: 10.5505/tjh.2012.10327. Epub 2012 Mar 5. Review.

3.

Manipulation of the hepcidin pathway for therapeutic purposes.

Fung E, Nemeth E.

Haematologica. 2013 Nov;98(11):1667-76. doi: 10.3324/haematol.2013.084624. Review.

4.

Post-diagnosis hemoglobin change associates with overall survival of multiple malignancies - results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers.

Wan S, Lai Y, Myers RE, Li B, Palazzo JP, Burkart AL, Chen G, Xing J, Yang H.

BMC Cancer. 2013 Jul 10;13:340. doi: 10.1186/1471-2407-13-340.

5.

Effects of funding policy changes and health warnings on the use of erythropoiesis-stimulating agents.

Weir MA, Gomes T, Winquist E, Juurlink DN, Cuerden MS, Mamdani M.

J Oncol Pract. 2012 May;8(3):179-83. doi: 10.1200/JOP.2011.000287. Epub 2012 Jan 17.

6.

Promotion of Myelopoiesis in Myelosuppressed Mice by Ganoderma lucidum Polysaccharides.

Zhu XL, Liu JH, Li WD, Lin ZB.

Front Pharmacol. 2012 Feb 24;3:20. doi: 10.3389/fphar.2012.00020. eCollection 2012.

7.

The prevalence and cost of unapproved uses of top-selling orphan drugs.

Kesselheim AS, Myers JA, Solomon DH, Winkelmayer WC, Levin R, Avorn J.

PLoS One. 2012;7(2):e31894. doi: 10.1371/journal.pone.0031894. Epub 2012 Feb 21.

8.

Non-blood medical care in gynecologic oncology: a review and update of blood conservation management schemes.

Simou M, Thomakos N, Zagouri F, Vlysmas A, Akrivos N, Zacharakis D, Papadimitriou CA, Dimopoulos MA, Rodolakis A, Antsaklis A.

World J Surg Oncol. 2011 Nov 3;9:142. doi: 10.1186/1477-7819-9-142. Review.

9.
10.

Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study.

Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH.

Cancer. 2011 Aug 15;117(16):3641-9. doi: 10.1002/cncr.25972. Epub 2011 Feb 24.

11.

Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer.

Chavez-MacGregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, Buchholz TA, Shih YC, Giordano SH.

Ann Oncol. 2011 Nov;22(11):2394-402. doi: 10.1093/annonc/mdq777. Epub 2011 Mar 10.

12.

EPO for stroke therapy - Is there a future for further clinical development?

Minnerup J, Wersching H, Schäbitz WR.

Exp Transl Stroke Med. 2010 May 12;2(1):10. doi: 10.1186/2040-7378-2-10. No abstract available.

13.

Targeting erythroblast-specific apoptosis in experimental anemia.

Diwan A, Koesters AG, Capella D, Geiger H, Kalfa TA, Dorn GW 2nd.

Apoptosis. 2008 Aug;13(8):1022-30. doi: 10.1007/s10495-008-0236-3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk